Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Interest Income

Income earned on cash, deposits, and investments held by the company.

Cellectis S.A.NASDAQ: CLLS

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income declines year over year

Q1 FY2026 interest income of $1.85M fell 36.4% year over year, behind the -30.9% change in trailing-twelve-month interest income. Sequentially, it fell 10.9% from the prior quarter. Over 3 fiscal years it compounded at +103.9% a year.

Context

  • Interest income amounted to 13.0% of revenue in FY2025, down 14.2 pp from a year earlier.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -36.4% toward the trailing-twelve-month pace of -30.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.85M-10.9% QoQ
Last fiscal yearDec 2025
$9.5M-15.8% YoY
LTMMar 2026
$8.47M-30.9% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-36.4%——
1 year-15.8%——
3-year CAGR+103.9%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
9.5M USD
Year-over-year change
-15.8%
4-year CAGR
+90.6%

Interest Income vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -30.9% is the 4th highest of 8, against a peer median of -40.4%.
  • Interest income amounts to 12.4% of revenue for CLLS, versus a peer median of 4.8%.
CLLS Competitors
Interest Income for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$10.41M USD-19.3%+56.7%4.8%
CLLSCellectis S.A.LTM Mar 2026$8.47M USD-30.9%+103.9%12.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$6.34M USD-30.5%+286.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.91M USD-45.8%+12.3%—
DBVTDBV Technologies S.A.LTM Mar 2026$2.21M USD+39.7%+14.0%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.84M USD-40.4%+46.2%367.5%
ACIUAC Immune S.A.LTM Mar 2026CHF 1.36M CHF-58.3%+200.1%36.6%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$944K USD-79.3%+28.9%—
SLNSilence Therapeutics plcLTM Mar 2026$0 USD—+148.8%0.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
KRROKorro Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding CLLS) —-40.4%+51.4%4.8%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.35M19.17M755K41.51M72.95M
Cost of Revenue1.84M8.48M7.42M9.18M9.8M
Gross Profit28.5M10.69M(6.66M)32.32M63.15M
Gross Margin93.9%55.7%-882.6%77.9%86.6%
Research & Development117.84M97.5M87.65M90.54M93.52M
Selling, General & Admin22.88M8.9M8.12M8.42M8.6M
Operating Expenses131.98M100.35M90.64M91.88M96.23M
Depreciation & Amortization14.16M18.44M18.52M19.85M20.06M
EBITDA(78.43M)(76.38M)(92.64M)(9.46M)(39.85M)
EBITDA Margin-258.4%-398.4%-12269.8%-22.8%-54.6%
Operating Income(103.48M)(89.67M)(97.3M)(59.55M)(33.08M)
Operating Margin-341.0%-467.7%-12887.7%-143.5%-45.3%
Interest Income719K1.12M3.61M11.28M9.5M
Interest Expense4.37M3.79M5.31M7.45M8.11M
Other Income / Expenses6.73M(8.94M)(19.16M)22.79M(34.94M)
Income Before Tax(96.75M)(98.6M)(116.46M)(36.76M)(68.02M)
Pre-Tax Margin-318.8%-514.3%-15425.7%-88.6%-93.2%
Income Tax Expense(3K)87K371K0(423K)
Net Income(114.2M)(106.14M)(101.06M)(36.76M)(67.59M)
Net Margin-376.3%-553.6%-13385.3%-88.6%-92.7%
EPS (Basic)(1.93)(2.33)(1.77)(0.41)(0.68)
EPS (Diluted)(1.93)(2.33)(1.77)(0.41)(0.68)
Weighted Avg Shares44.82M45.55M57.01M90.57M100.28M
Weighted Avg Shares (Diluted)44.82M45.55M57.01M90.57M100.28M

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.